Loading patent…
AssigneeGenmab B.V.
InventorsJanine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G.J. Van De Winkel, Denise Leah Williams, Jorgen Petersen, Ole Baadsgaard D.M. Sc.
Estimating the term…
Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
An isolated human monoclonal antibody which binds to human CD25 and inhibits IL-2 binding to CD25.
An isolated human monoclonal antibody which binds to human CD25 comprising at least one CDR sequence selected from the group consisting of:
An isolated human monoclonal antibody which binds to human CD25 comprising at least one CDR sequence selected from the group consisting of:
An isolated human monoclonal antibody which binds to human CD25 comprising at least one CDR sequence selected from the group consisting of:
An isolated human monoclonal antibody which binds to human CD25 comprising at least one CDR sequence selected from the group consisting of:
An isolated human antibody comprising a heavy chain variable region amino acid sequence derived from a human VH1-69/JH4b or VH1-69/JH5b germline sequence and a light chain variable region amino acid sequence derived from a human A27/JK4 or A27/Jk5 germline sequence, wherein the human antibody binds to human CD25.
An isolated human antibody comprising a heavy chain variable region amino acid sequence derived from a human VH1-69/D7-27/JH4b or VH1-69/D7-27/JH5b germline sequence and a light chain variable region amino acid sequence derived from a human A27/JK4 or A27/JK5 germline sequence, wherein the human antibody binds to human CD25.
A hybridoma comprising a B cell obtained from a transgenic nonhuman animal in which V-(D)-J gene segment rearrangements have resulted in the formation of a functional human heavy chain transgene and a functional light chain transgene fused to an immortalized cell, wherein the hybridoma produces a detectable amount of the monoclonal antibody of any one of the preceding claims.
A method of producing a human monoclonal antibody which binds to human CD25, comprising:
An expression vector comprising a nucleotide sequence encoding the variable region of a light chain, heavy chain or both light and heavy chains of a human antibody which binds to human CD25.
An expression vector comprising a nucleotide sequence encoding a heavy chain variable region comprising a nucleotide selected from the group consisting of the nucleotide sequences as set forth in SEQ ID NOs:
An expression vector comprising a nucleotide sequence encoding a heavy chain variable region comprising an amino acid sequence selected from the group consisting of the amino acid sequences as set forth in SEQ ID NOs:2, 6, 10, or 14 and a light chain variable region comprising the amino acid sequence selected from the group consisting of the amino acid sequences as set forth in shown in SEQ ID NOs:
An anti-idiotypic antibody binding to AB1, AB7, AB11 or AB12.
Dependencies are inferred from the claim text.